Floatz logo

DOTA-PABZA-DIG-DPHE-GLN-TRP-ALA-VAL-GLY-HIS-NHCH(CH2CH(CH3)2)2

Metastatic Neuroendocrine Prostate Cancer

Novartis Pharmaceuticalsprotein_peptidePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Metastatic Neuroendocrine Prostate Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Phanes Therapeutics
Phase 2BB
Oxodotreotide
Novartis Pharmaceuticals
Phase 2B
Tarlatamab
Inkeun Park
Phase 2B
Alisertib
Weill Medical College of Cornell University
Phase 2B
Nivolumab
Andrew J. Armstrong, MD
Phase 2CCC

View all 35 →

Same molecule, other indications

DOTA-PABZA-DIG-DPHE-GLN-TRP-ALA-VAL-GLY-HIS-NHCH(CH2CH(CH3)2)2 is also rated in:

breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →